- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Provectus gains patent allowance for PH-10 in the EU
Knoxville, Tenn. - Provectus Pharmaceuticals has received allowance of its patent application in the European Union to cover PH-10, as well as other related agents and their use, Businesswire reports.
Knoxville, Tenn.
- Provectus Pharmceuticals has received allowance of its patent application in the European Union for PH-10, as well as other related agents and their use, according to Businesswire.
The pending patents cover topical applications for treatment of psoriasis and eczema. Currently, PH-10 is undergoing a phase 2 clinical trial in New York City for the treatment of moderate to severe psoriasis, Businesswire reports.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
